Stockreport

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF Novel assay developed to assess the extent of alpha-dystroglycan (?DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease in the ratio of gl [Read more]